Ranbaxy

Ranbaxy News

SC asks ex-Ranbaxy promoters on how they will comply with Rs 3500 crore arbitral award

The apex court was hearing the plea of Japanese firm Daiichi Sankyo which is seeking to recover Rs 3,500 crore, awarded to it by a Singapore tribunal in its case against Malvinder and Shivinder Singh.

Families of Ethiopian plane disaster victims steel themselves for journey to crash site

After the brief Q and A session, the Ethiopian mourners filed silently out of the room and slowly boarded the convoy of eight Ethiopian Airlines buses. The mourners looked like travelers themselves. Except they carried no luggage, only items to honour the dead in their final resting place.

Advertising

Malvinder Singh disobeyed orders, Delhi HC directs him to deposit SG$3.5 million

In April, Singh had allegedly sold 45 lakh equity shares held in RHT for around SG$3.5 million towards payment of an EMI on a property in Singapore.

Upcoming payouts a possible trigger for Singh brothers feud

In February, Delhi HC upheld the Singapore arbitration tribunal’s decision to fine the brothers for around Rs 3,500 crore for “concealing and misrepresenting” facts.

Delhi High Court questions former Ranbaxy promoters Malvinder and Shivinder Singh, bars from selling assets

Questioning the brothers in open court on bank accounts and properties in India and abroad, the bench asked them to reveal the assets sold since April 2016 before September 5, which is the next date of hearing.

HC restrains ex-Ranbaxy promoters from selling assets till Feb 26

The court restrained the former Ranbaxy promoters and brothers, Malvinder Singh and Shivinder Singh, and 12 others from selling or transferring their shares or any movable or immovable property till February 26, the next date of hearing, as disclosed by them before the high court earlier.

Advertising

2008 Ranbaxy stake sale: Singh brothers asked to pay Rs 2,562 cr to Daiichi Sankyo

Ex-promoters ‘concealed and misrepresented information’: Singapore tribunal.

Sun Pharma shares tank 15%; m-cap dips by Rs 34,055 cr

As a part of the integration process with Ranbaxy, the company expects to incur certain integration charges in order to generate long-term synergies from this merger, Sun Pharma said on Monday.

Govt gets NPPA to back off, controls on 7% of market to go

Major beneficiaries of the decision are Ranbaxy, GSK, Sanofi and Abbott.

Pfizer, Ranbaxy win dismissal of lawsuit over generic cholesterol drug Lipitor

Pfizer and Ranbaxy were accused of conspiring to delay sales of generic versions of Lipitor.

Advertising